Skip to main content
Erschienen in: Supportive Care in Cancer 3/2010

01.03.2010 | Original Article

Oral administration of analgesia and anxiolysis for pain associated with bone marrow biopsy

verfasst von: Giampaolo Talamo, Jason Liao, Michael G. Bayerl, David F. Claxton, Maurizio Zangari

Erschienen in: Supportive Care in Cancer | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Aims

Medical literature provides only scarce data about the degree of pain experienced by patients undergoing a bone marrow aspiration and biopsy (BMAB), and little is known about the factors that can modify the perception of pain. In this study, we evaluated the effectiveness of a combination of analgesia and anxiolysis in reducing the pain score of patients undergoing BMAB.

Materials and methods

Eighty-four consecutive adult patients underwent BMAB after local anesthesia with 5 mL of lidocaine hydrochloride 1% aqueous solution in the left posterior superior iliac crest. Analgesia was obtained with acetaminophen 650 mg and oxycodone 10 mg, and anxiolysis was obtained with lorazepam 2 mg, all drugs given once orally 30 min before the procedure. We assessed the pain level with the Wong–Baker Faces Pain Rating Scale, which distinguishes six levels of pain, from 0 to 5.

Results

The 34 patients who received an oral administration of analgesia and anxiolysis reported pain at lower levels, i.e., in the range of 0–2, more frequently than the 50 patients who underwent BMAB without analgesia/anxiolysis (78% vs 64%, respectively). Among several predictors analyzed using a multivariate regression model, three were found to be associated with decreased pain level: the use of analgesia/anxiolysis, male sex, and increase in age (all with p values <0.05). Length of the extracted bone specimen, body mass index, and need of a spinal needle for anesthesia in obese patients did not predict for pain level.

Conclusions

An oral administration of prophylactic regimen of analgesia and anxiolysis, at the above-mentioned doses, produced a statistically significant reduction of the perception of pain in patients undergoing BMAB, but its effect did not seem to provide a major and clinically significant reduction of pain level.
Literatur
1.
Zurück zum Zitat Vanhelleputte P, Nijs K, Delforge M, Evers G, Vanderschueren S (2003) Pain during bone marrow aspiration: prevalence and prevention. J Pain Symptom Manage 26:860–866CrossRefPubMed Vanhelleputte P, Nijs K, Delforge M, Evers G, Vanderschueren S (2003) Pain during bone marrow aspiration: prevalence and prevention. J Pain Symptom Manage 26:860–866CrossRefPubMed
2.
Zurück zum Zitat Burkle CM, Harrison BA, Koenig LF, Decker PA, Warner DO, Gastineau DA (2004) Morbidity and mortality of deep sedation in outpatient bone marrow biopsy. Am J Hematol 77:250–256CrossRefPubMed Burkle CM, Harrison BA, Koenig LF, Decker PA, Warner DO, Gastineau DA (2004) Morbidity and mortality of deep sedation in outpatient bone marrow biopsy. Am J Hematol 77:250–256CrossRefPubMed
3.
Zurück zum Zitat Dunlop TJ, Deen C, Lind S, Voyle RJ, Prichard JG (1999) Use of combined oral narcotic and benzodiazepine for control of pain associated with bone marrow examination. South Med J 92:477–480CrossRefPubMed Dunlop TJ, Deen C, Lind S, Voyle RJ, Prichard JG (1999) Use of combined oral narcotic and benzodiazepine for control of pain associated with bone marrow examination. South Med J 92:477–480CrossRefPubMed
4.
Zurück zum Zitat Milligan DW, Howard MR, Judd A (1987) Premedication with lorazepam before bone marrow biopsy. J Clin Pathol 40:696–698CrossRefPubMed Milligan DW, Howard MR, Judd A (1987) Premedication with lorazepam before bone marrow biopsy. J Clin Pathol 40:696–698CrossRefPubMed
5.
Zurück zum Zitat Gudgin EJ, Besser MW, Craig JI (2008) Entonox as a sedative for bone marrow aspiration and biopsy. Int J Lab Hematol 30:65–67PubMed Gudgin EJ, Besser MW, Craig JI (2008) Entonox as a sedative for bone marrow aspiration and biopsy. Int J Lab Hematol 30:65–67PubMed
6.
Zurück zum Zitat Steedman B, Watson J, Ali S, Shields ML, Patmore RD, Allsup DJ (2006) Inhaled nitrous oxide (Entonox) as a short acting sedative during bone marrow examination. Clin Lab Haematol 28:321–324CrossRefPubMed Steedman B, Watson J, Ali S, Shields ML, Patmore RD, Allsup DJ (2006) Inhaled nitrous oxide (Entonox) as a short acting sedative during bone marrow examination. Clin Lab Haematol 28:321–324CrossRefPubMed
9.
Zurück zum Zitat Hockenberry MJ, Wilson D, Winkelstein ML (2005) Wong’s essentials of pediatric nursing. Mosby, St. Louis 1259 Hockenberry MJ, Wilson D, Winkelstein ML (2005) Wong’s essentials of pediatric nursing. Mosby, St. Louis 1259
10.
Zurück zum Zitat von Gunten CF, Soskins M (2007) Bone marrow biopsy symptom control and palliative care consultation. J Pain Symptom Manag 33:236–237CrossRef von Gunten CF, Soskins M (2007) Bone marrow biopsy symptom control and palliative care consultation. J Pain Symptom Manag 33:236–237CrossRef
11.
Zurück zum Zitat Niesel HC (1997) Local anesthetics–maximum recommended doses. Anaesthesiol Reanim 22:60–62PubMed Niesel HC (1997) Local anesthetics–maximum recommended doses. Anaesthesiol Reanim 22:60–62PubMed
Metadaten
Titel
Oral administration of analgesia and anxiolysis for pain associated with bone marrow biopsy
verfasst von
Giampaolo Talamo
Jason Liao
Michael G. Bayerl
David F. Claxton
Maurizio Zangari
Publikationsdatum
01.03.2010
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 3/2010
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-009-0652-0

Weitere Artikel der Ausgabe 3/2010

Supportive Care in Cancer 3/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.